Webinars
28th February, 2012
Improving the Efficiency of Clinical Studies:When to Re-Estimate the Sample Size?
9th February, 2012
Evolution of a new PRO measure supporting a recent label claim
25th January, 2012
Strategies for implementing CDISC standards: Avoiding the Pitfalls when Converting Legacy Data
17th November, 2011
Measurement in Clinical Trials: FDA position on review and qualification of Clinical Outcome Assessments
3rd November, 2011
Adjudication Committees: Functions, Tips and Technologies
13th October, 2011
FDA Final Rule on Safety Information During Clinical Trials: What impact will this have for sponsors on adverse event reporting?
22nd September, 2011
Maintaining Specimen Integrity in Extreme Weather Conditions:How can you ensure that your sample integrity is not being compromised?
13th July, 2011
Imaging in Rheumatoid Arthritis Trials: Expectations, Tips and Suggestions for Integration into Clinical Trials
23rd March, 2011
The High Stakes of Running an Oncology Trial: Why have some recent Studies Failed?
8th March, 2011
Biomarkers in the Clinical development of Alzheimers Disease Agents
21st February, 2011
Biosimilar Drug Development – the impact of draft CHMP guidelines
10th February, 2011
Implications of Revised FDA CV Endpoint Definitions on Cardiovascular, Obseity, and Diabetes Drug Development
16th December, 2010
Standard Cardiovascular End-Point Definitions – Practical Implications for the Design and Data Collection of CV Outcome Trials.
20th October, 2010
Biomarkers in Oncology Trials: Current Concepts and FDA Expectations
29th September, 2010
Update of FDA and Diabetes - Lessons Learned from the Avandia Advisory Panel
24th June, 2010
Innovative Solutions for Managing and Analyzing Local Laboratory Data in Clinical Trials
4th May, 2010
Implications of the FDA’s Updated Definitions for Standardized Data Collection for Cardiovascular Trials
24th March, 2010
Glucose Clamp Techniques for Advancing the Development of Diabetes Type I and Type II Therapeutic Agents
9th February, 2010
